Climbing Death Hill: Aemetis and the Third Leg of the Bioeconomy Triathlon

After twenty years of endurance, Aemetis faces the steepest grade in industrial biotechnology.

The cyclist comes hammering into the transition zone, twenty-five miles of scorched blacktop behind him, his jersey salt-caked and fluttering in the Central Valley wind. His lungs burn. His legs ache. But he is upright, unbroken, and remarkably intact.

Behind him lies the Lake of Death. In those murky waters, where brilliant ideas born in 500-milliliter Erlenmeyer flasks encountered the unforgiving realities of commercial-scale engineering, an entire generation of bioeconomy flagships went down. The rusted hulls of Range Fuels, KiOR, and others lie scattered across the lakebed.

Beyond that came the Valley of Death, forty grueling kilometers of volatile commodity spreads, fickle offtakers, shifting mandates, and relentless cash burn. He survived the swim. He crossed the valley. Now he looks toward the final leg. Death Hill.

Ten kilometers of asphalt rising brutally toward the clouds. The road is steep, unforgiving, and narrow, littered with the hopes of contenders who looked like world-beaters coming off the bicycle, only to collapse when the asphalt pitched toward the heavens. They say it’s mostly downhill on the other side. First, you have to get over the hill.

Welcome to the Aemetis Triathlon.

Leg One: The Swim. Build It.

The opening discipline of the bioeconomy journey is a brutal Darwinian sorting mechanism where pristine laboratory models collide violently with the messy realities of pipe stress, metallurgy, slagging, foaming, and pump cavitation.

It is the place where industrial dreams go to meet the unforgiving second law of thermodynamics, seeking mercy and receiving only justice.

Aemetis, founded in 2006 by Eric McAfee, made a foundational decision that separated it from many of the high-flying cellulosic dreamers of the George W. Bush era. While competitors were spending hundreds of millions building bespoke monuments to uncooperative enzymes, Aemetis acquired the idled Keyes ethanol facility in California’s Central Valley in 2012, setting about transforming a distressed industrial asset into an operating renewable fuels platform.

It crossed an ocean to establish a large-scale biodiesel refinery in Kakinada, India. Having established a foothold on dry land, it dove headlong into the manure lagoons of the Central Valley.

And this is where the engineering story becomes particularly interesting.

Aemetis did not simply construct concrete-tank anaerobic digesters beside dairy barns. It engineered and permitted a 36-mile network of underground gathering pipelines, slicing through the agricultural heart of Stanislaus and Merced counties, connecting dairy operations to a central biogas upgrading facility at Keyes. There, captured methane is cleaned, upgraded to pipeline quality, and injected into the PG&E natural gas system. On October 22, Aemetis announced that two more dairy digesters had commenced operation, bringing the network to 14 digesters serving 17 dairies.

There are more digesters to construct, more infrastructure to complete, and plenty of engineering challenges still ahead. But this is not an animation designed for a pitch deck. That is infrastructure. Aemetis survived the Lake of Death.

Leg Two: The Bike. Make It Pay.

The moment an industrial enterprise begins to establish its infrastructure, the question changes. Can this machine generate enough cash to outrun its depreciation, operating costs, and relentless demands for reinvestment?

For years, conventional observers viewed Aemetis as a hardscrabble commodity grinder—an enterprise trapped on the margin treadmill, hedging corn against ethanol in California, chasing biodiesel feedstock spreads in India, and pouring capital into a dairy biogas dream that seemed perpetually just out of reach.

This is Leg Two: The Bike.

And something extraordinary happened on the ride across the Valley of Death. The alchemy of the modern regulatory carbon market began to work in Aemetis’s favor. A unit of methane combusted in a heavy-duty engine is merely a source of thermal energy, worth perhaps three dollars per MMBtu at the Henry Hub benchmark. But methane intercepted from a dairy manure lagoon becomes something rather different: a source of energy whose environmental benefits can be certified, traded, and monetized. Under the federal Renewable Fuel Standard, that renewable gas can generate D3 RIN credits. Under California’s Low Carbon Fuel Standard, it can generate additional value according to the carbon intensity of its production pathway.

Then arrived September 8, 2026, and with it a consequential revision of the federal 45ZCF-GREET lifecycle model. The regulatory architects in Washington adjusted their calculations, and the economic architecture of dairy renewable natural gas shifted on its axis. According to Aemetis, the potential gross value of its Section 45Z production tax credits rose from approximately $15 to $62 per MMBtu, before transaction fees and market discounts.

The financial harvest was immediate. On November 5, Aemetis delivered a third-quarter earnings report that might have caused even hardened Wall Street observers to sit up and rub their eyes. Revenues climbed 49 percent year-over-year to $88.2 million. Operating income reached $20.9 million. Adjusted EBITDA swung from negative $5.0 million in the third quarter of 2025 to positive $24.8 million. And, most startling of all for a sector accustomed to apologizing for its bottom line, the company reported $5.2 million in GAAP net income, compared with a $23.7 million net loss one year earlier.

There are qualifications. The quarter included approximately $11 million in retroactive 45Z adjustments relating to earlier 2026 production. Aemetis still reported a $25.9 million net loss for the first nine months of the year. One profitable quarter is not the same thing as a durable earnings record. But the improvement is substantial, and this is not entirely a matter of accounting recognition. Aemetis received $22.4 million in cash from the sale of 45Z credits in September.

On November 10, Aemetis announced that the California Air Resources Board had provisionally approved six additional dairy RNG pathways under the LCFS program, effective October 1, carrying an extraordinary average carbon-intensity score of negative 351. Combined with seven pathways previously approved in 2025, these provide more opportunities for the company to generate valuable California low-carbon fuel credits, subject to actual production volumes and prevailing market prices. The company is also advancing mechanical vapor recompression at Keyes, a project intended to displace approximately 80 percent of the facility’s fossil natural gas consumption with electricity, potentially lowering its carbon intensity and strengthening its 45Z economics.

The Valley of Death has not magically disappeared. Commodity prices still fluctuate. Carbon markets remain vulnerable to policy changes. Scaling the dairy network remains expensive.

But the cyclist has found his rhythm. There is speed in the wheels, strength in the legs, and a genuine prospect of reaching the finish line. Which brings us to the bicycle.

The Bicycle That Crossed the Valley

Before we send our weary competitor into the crucible of Death Hill, justice demands that we pause, take off our hats, and raise a glass to the indispensable partner who made much of this journey possible. Third Eye Capital.

It is an unfortunate habit among clean-tech commentators to cast high-yield, opportunistic lenders as the villains of the drama—predatory financiers demanding their pound of flesh from virtuous green crusaders. That is romantic nonsense. When an industrial pioneer is standing at the edge of the Valley of Death, the blue-blood, white-shoe bankers do not generally ride to the rescue. They want established cash flows, tested technologies, predictable earnings, strong collateral, and operating histories. Quite understandably. Those are the foundations of conventional commercial lending. But someone has to provide capital before all those things exist. Third Eye Capital was willing to do that. It helped finance Aemetis through years of construction, commercial uncertainty, regulatory delays, permitting challenges, and red ink. It amended agreements, granted waivers, and accommodated changing circumstances as the industrial assets developed.

Naturally, Third Eye charged for the privilege. When you finance a crossing of the Valley of Death, you do not charge suburban mortgage rates. You are underwriting a future that may never arrive. As of September 30, Aemetis reported approximately $280.6 million outstanding under Third Eye Capital notes, including principal, accrued interest, and financing fees, net of discounts. Major tranches carried interest rates between 16.0 percent and an eye-watering 20.75 percent. Those are extraordinary financing costs by the standards of mature industrial enterprises.

Yet, without risk-tolerant financiers like Third Eye, the bioeconomy would have fewer operating plants and considerably more attractive artist’s renderings. Third Eye deserves a place among the heroes of this story. It gave Aemetis the bicycle. And it helped get the company across the Valley of Death. But, you cannot run the final leg of a triathlon wearing cycling cleats. You cannot push the bicycle up Death Hill. And you certainly cannot keep paying indefinitely for expensive racing equipment once the race has changed disciplines.

Leg Three: The Run. Make It Last.

And so our runner stands at the base of Death Hill, staring up into the fog. The balance sheet that brought him to this point is wound so tight that one can almost hear the cables groaning under the strain. Total debt at September 30: $435.4 million. Debt classified as current or due on demand: $376.9 million.  During the first nine months of 2026, interest and debt-amortization expense, together with preferred-unit accretion, amounted to approximately $46.9 million. Looming on the calendar is a $117.3 million redemption obligation associated with Aemetis Biogas preferred units, scheduled for December 31, 2026. There is a contractual fallback if redemption does not occur, but it brings additional financing costs and restrictions, including a sweep of available free cash flow.

This is Death Hill.

Yet there is a tantalizing opportunity here. Suppose Aemetis could refinance approximately $280 million of expensive Third Eye obligations into conventional long-term financing at an interest rate five percentage points lower. The simple annualized interest savings would be approximately $14 million. Reduce the rate by eight percentage points, and the potential annualized savings approach $22 million. These are illustrative calculations, not forecasts or promised cash savings. Actual refinancing economics would depend on fees, accrued obligations, repayment schedules, collateral, covenants, and the rates lenders are prepared to offer. But the magnitude of the opportunity is unmistakable.

Twenty-two million dollars a year is not a rounding error. It is money that could strengthen debt-service coverage, finance maintenance and expansion, support additional digesters, and provide a cushion against regulatory and commodity-market turbulence. Aemetis knows the map. Several possible routes are already under active exploration. A long-term commercial refinancing secured against the established Keyes ethanol facility. A proposed initial public offering of its Universal Biofuels subsidiary in India, where an operating biodiesel business may offer access to a different pool of capital. Additional project financing and tax-credit monetization, alongside the USDA-guaranteed financing already supporting portions of its dairy RNG network at substantially lower interest rates than the most expensive Third Eye obligations.

These are possibilities, not completed financings. Their timing, proceeds, and availability remain uncertain. But there is a powerful economic logic behind the effort. Cheaper financing leaves more operating cash within the business. More retained cash strengthens debt-service coverage.

Yet, high-interest debt consumes the cash needed to improve the balance sheet.  Aemetis has begun demonstrating the profitability that could justify cheaper financing. But it must obtain it to retain more of the profitability it has begun demonstrating.

That is the paradox of Death Hill, and the ticking clock.

The Summit

We return to our athlete, standing on the rubber matting of the transition zone.

The Lake of Death is behind him. The Valley of Death has been crossed. The engineering works. The plants operate. The carbon credits are being monetized. And for one remarkable quarter, the company has shown that the enterprise can produce a profit. Third Eye Capital deserves a standing ovation for getting the rider this far.  They supplied the bicycle. They kept faith with the journey, and they collected their coupon.

Now comes the paradox of success.

The better Aemetis performs, the stronger the argument that it no longer needs the extraordinarily expensive financing that helped make its performance possible. The first two legs have given Aemetis something it did not possess before: a credible case for refinancing. Not a guaranteed case. Not an irresistible case. But one supported by operating infrastructure, measurable production, monetized carbon credits, and evidence that the business can generate substantial profits.

Will that be enough? Will the capital markets recognize the risk that Aemetis has retired and distinguish it from the risk that remains? Will conventional lenders arrive with long-term financing at costs that an industrial company can sustainably bear? And, above all, will they arrive in time?

There’s a finish line somewhere beyond Death Hill. They say the road gets easier once you reach the summit. But the hill is steepest at the bottom. And you can’t climb it carrying the bicycle.

Lace up the shoes. Run.

Category: Top Stories